Bronchospasm after timolol administration
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F25%3A10499266" target="_blank" >RIV/00216208:11150/25:10499266 - isvavai.cz</a>
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=hh0YZltdnX" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=hh0YZltdnX</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5114/ait/200233" target="_blank" >10.5114/ait/200233</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Bronchospasm after timolol administration
Popis výsledku v původním jazyce
Timolol is a non-selective b-adrenergic receptor-blocking agent. It is topically administered in patients suffering from open-angle glaucoma or ocular hypertension. Among this patient population, timolol is usually prescribed alongside prostaglandin analogues. The prevalence of glaucoma increases with age. Most patients treated with timolol for glaucoma are of advanced age and may have various comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease (COPD), and arterial hypertension. Notably, in the female population with COPD, the prevalence of open-angle glaucoma is significantly higher than in the general population. Timolol's systemic absorption and central nervous system penetration can lead to several side effects, including bradycardia, bronchospasm, increased fatigue, or confusion. We would like to present two cases wheretimolol administration resulted in severe, life-threatening bronchospasm, followed by hypoxic cardiac arrest in patients with COPD and asthma.
Název v anglickém jazyce
Bronchospasm after timolol administration
Popis výsledku anglicky
Timolol is a non-selective b-adrenergic receptor-blocking agent. It is topically administered in patients suffering from open-angle glaucoma or ocular hypertension. Among this patient population, timolol is usually prescribed alongside prostaglandin analogues. The prevalence of glaucoma increases with age. Most patients treated with timolol for glaucoma are of advanced age and may have various comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease (COPD), and arterial hypertension. Notably, in the female population with COPD, the prevalence of open-angle glaucoma is significantly higher than in the general population. Timolol's systemic absorption and central nervous system penetration can lead to several side effects, including bradycardia, bronchospasm, increased fatigue, or confusion. We would like to present two cases wheretimolol administration resulted in severe, life-threatening bronchospasm, followed by hypoxic cardiac arrest in patients with COPD and asthma.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30223 - Anaesthesiology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anaesthesiology Intensive Therapy
ISSN
1642-5758
e-ISSN
1731-2531
Svazek periodika
57
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
PL - Polská republika
Počet stran výsledku
2
Strana od-do
"e130"-"e131"
Kód UT WoS článku
001521457400002
EID výsledku v databázi Scopus
2-s2.0-105010161601